RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
WuXi Biologics, a China biologics CRO/CMO, has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will be WuXi Biologics’ 12th drug substance manufacturing facility. By 2022, WuXi plans to have a total production capacity of 220,000 liters, with facilities around the world, including China, Ireland, Singapore and US. Initially, the Chengdu facility will have a bioreactor capacity of 48,000 liters.
Source: China Biotoday
